Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of astragaloside in treating delayed type hypersensitivity mediated diseases

A technology of astragaloside IV and hypersensitivity, which is applied in the field of medicine, can solve the problems of prevention and treatment of diseases mediated by astragaloside IV, and achieve the reduction of pathological and histological damage and inflammation The effect of the reaction

Inactive Publication Date: 2010-03-10
NANJING UNIVERSITY OF TRADITIONAL CHINESE MEDICINE
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] After tracking the latest literature reports, there is no research on the prevention and treatment of diseases mediated by astragaloside IV

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of astragaloside in treating delayed type hypersensitivity mediated diseases
  • Application of astragaloside in treating delayed type hypersensitivity mediated diseases
  • Application of astragaloside in treating delayed type hypersensitivity mediated diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] Example 1 The inhibitory effect of astragaloside IV on delayed-type hypersensitivity has the following experimental evidence:

[0034] Effect of Astragaloside IV on Allergic Contact Dermatitis Mouse Model

[0035] Methods: ICR clean level mice were adaptively fed for 3 days and divided into 8 groups, namely model group, dexamethasone group (0.65mg / kg), astragaloside IV induction phase administration (5mg / kg group, 10mg / kg kg group, 20mg / kg group), astragaloside IV effect administration (5mg / kg group, 10mg / kg group, 20mg / kg group). The administration of astragaloside IV (intraperitoneal injection) in the induction phase was administered daily from the first day of modeling, and the administration was stopped on the day before the challenge; the administration of astragaloside IV (intraperitoneal injection) in the effect phase was administered at 0h and 5h after the challenge , 9h, 18h and 24h administration; the dexamethasone group was administered intraperitoneally eve...

Embodiment 2

[0042] Example 2 Application of Astragaloside IV in the Preparation of Drugs for the Treatment of Delayed Hypersensitivity Diseases

[0043] The dosage of astragaloside IV in the present invention varies due to different dosage forms. The general dosage is 50mg-400mg orally per person per day, and the dosage for injection is 50mg-150mg. (estimated from animal dose)

[0044] When the medicine of the present invention is used as an anti-delayed hypersensitivity disease, it can be administered through the skin, mucous membranes, enteral and parenteral, and can be made into solid form tablets, capsules, granules, powders, or Ointment or ointment in semi-solid form, or powdered injection, or dosage forms such as injection, suspension, emulsion or liniment in liquid form for clinical application. The above-mentioned medicines in various dosage forms can be prepared according to conventional methods in the field of pharmacy. Delayed hypersensitivity diseases include contact dermati...

Embodiment 3

[0046] Example 3 Preparation of Astragaloside IV Sodium Chloride Injection

[0047] Weigh 10g of astragaloside IV, add 2L each of ethanol and propylene glycol in turn, stir to dissolve, add 900g of sodium chloride, add water for injection to 100L, mix well, filter and sterilize, sub-package, 100ml per bottle, potting, to obtain 10mg / 100ml sterilized Astragaloside IV Sodium Chloride Injection.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
The average particle sizeaaaaaaaaaa
Login to View More

Abstract

The invention relates to an application of astragaloside in preparing a medicament for treating delayed type hypersensitive diseases, an application of astragaloside in preparing a medicament for treating contact dermatitis, an application of astragaloside in preparing a medicament for treating hypersensitive pneumonia, an application of astragaloside in preparing a medicament for treating homograft rejection and an application of astragaloside in preparing a medicament for treating granulomatosis caused by intracellular pathogens. The astragaloside as a main active ingredient for treating thedelayed hypersensitive diseases can markedly inhibit delayed type allergy mediated diseases and is likely to become a higher effective and lower toxic medicament for treating the delayed type hypersensitive diseases.

Description

technical field [0001] The invention relates to the application of astragaloside IV, in particular to its application in the field of medicine. Background technique [0002] Prior Art: Delayed type hypersensitivity (DTH, also known as type IV hypersensitivity) includes the immune response mediated by sensitized T cells and the resulting tissue and cell damage. Cellular immunity refers to the host immune response that stimulates the local production of cytokines in the presence of antigens and is characterized by the proliferation of specific T cells. These cytokines attract monocytes from the blood to the site of damage and activate the immune process. DTH is an immune response process similar to the cellular immune process that includes the action of T cells and cytokines. The expression of DTH depends largely on the cytokines released by Th1 cells, so the induction of Th1 is of signal importance. Th1 is activated by recognizing the complex of MHC class II molecules and ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/7048A61P37/02A61P17/00A61P11/00A61P37/06A61P37/08
Inventor 洪敏
Owner NANJING UNIVERSITY OF TRADITIONAL CHINESE MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com